NCT04142515

Collection and Analysis of the Clinical and Biological Characteristics of Patients Treated for Giant Cells ARTEitis (Horton's Disease)

Collection and Analysis of the Clinical and Biological Characteristics of Patients Treated at Nîmes Carémeau University Hospital, for Giant Cells ARTEitis (Horton's Disease), for Diagnosis and During Long-term Follow-up

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 83 (actual)
• Sponsor: Centre Hospitalier Universitaire de Nīmes · Academic / Other
• Sex: All
• Age: 45 Years
• Healthy volunteers: Not accepted

Summary

Giant cell arteritis (GCA) or Horton's disease: frequent large vessel vasculitis (cephalic) (incidence estimated at 9 per 100,000 in France), potentially responsible for blindness. Treatment: corticosteroid therapy, which is effective in the vast majority of cases. Clinical problem: relapse; 36% to 44% of patients have a relapse that occurs in the first year for many patients, requiring a re-escalation of corticosteroid therapy, with its consequences: * Cumulative dose of corticosteroid therapy that causes cardiovascular and infectious morbidity. * Requires additional immunosuppressive treatment.

Conditions

• Giant Cell Arteritis
• Horton Disease

Interventions

Type	Name	Description
OTHER	no intervention	no intervention

Timeline

• Start date: 2020-02-01
• Primary completion: 2021-03-31
• Completion: 2021-03-31
• First posted: 2019-10-29
• Last updated: 2022-09-26

Locations

1 site across 1 country: France